Ipamorelin

The defining feature of ipamorelin is its ability to stimulate a clean pulse of growth hormone from the pituitary. A clinical pharmacokinetic study in healthy male volunteers characterized this response in detail across five infusion doses (4). Ipamorelin produced a single episode of GH release peaking at roughly 40 minutes, followed by an exponential decline back to baseline. The peptide itself showed a terminal half-life of about two hours and dose-proportional behavior, meaning higher doses produced predictably larger exposures (4).

Laboratory work on the pituitary cells responsible for GH production helps explain what's happening at the cellular level. Chronic ipamorelin treatment increased the volume density of secretion granules — the tiny packets that store GH inside somatotroph cells — and primed those cells to release more hormone when stimulated again (1). This suggests ipamorelin doesn't just trigger a one-time release; it appears to enhance the pituitary's overall capacity to store and release GH over time (1).

A comparative pharmacokinetic analysis also found that ipamorelin clears the body about five times more slowly than GHRP-6, an earlier secretagogue, with roughly 60–80% recovered intact (5). This metabolic stability may contribute to its consistent dose-response profile.

Some of the most striking findings on ipamorelin involve bone. A 15-day study examining longitudinal bone growth showed that ipamorelin dose-dependently increased the growth rate of the tibia, from 42 micrometers per day at baseline up to 52 micrometers per day at the highest dose tested (3). Notably, this happened without major changes in circulating IGF-I, IGF binding proteins, or standard markers of bone turnover — suggesting the effect on bone may involve local mechanisms beyond the classic GH/IGF-I axis (3).

A separate three-month study looked at whether ipamorelin could counteract the bone-thinning effects of glucocorticoid treatment, a well-known cause of skeletal weakening (2). Subjects receiving glucocorticoids alone showed the expected decrease in bone formation; those receiving ipamorelin alongside the glucocorticoid showed a four-fold increase in periosteal bone formation rate compared to glucocorticoid-only controls (2). The combination group also showed significantly improved muscle strength, measured as maximum tetanic tension in the calf muscles (2).

Taken together, these results suggest ipamorelin may help preserve or build bone and muscle tissue under conditions that would otherwise drive catabolism.

The glucocorticoid study mentioned above is also informative for thinking about ipamorelin in recovery contexts more broadly (2). Glucocorticoids — whether endogenous stress hormones or pharmaceutical steroids — drive muscle breakdown and impair bone formation. Ipamorelin's ability to push back against both effects suggests it may have value as a recovery agent in situations involving high cortisol or catabolic pressure.

The muscle strength findings are notable because they were measured directly through mechanical testing rather than inferred from body weight or composition (2). A four-fold increase in periosteal bone formation rate alongside preserved muscle tension points to coordinated anabolic effects on the musculoskeletal system as a whole.

The pharmacokinetic profile (4, 5) supports practical considerations around dosing — ipamorelin's short half-life means it produces a discrete GH pulse rather than sustained elevation, and intranasal delivery has been characterized with a bioavailability around 20%, lower than some comparators but still indicating the peptide can cross mucosal barriers (5).

Reported side effects in the published research are minimal. The clinical pharmacokinetic study in healthy volunteers across five dose levels did not report significant adverse events, and ipamorelin's selectivity for GH release — without meaningfully disturbing cortisol or prolactin — is one of the reasons it drew research interest in the first place (4). Anecdotally, some users report mild flushing, light-headedness, or transient hunger shortly after administration, reflecting the peptide's ghrelin-receptor activity.

The body of ipamorelin evidence comes primarily from preclinical and laboratory work, with limited human clinical data so far. Long-term safety in humans hasn't been formally characterized because the necessary large-scale trials haven't been completed. Growth hormone secretagogues as a class are prohibited in competitive sport under World Anti-Doping Agency rules — relevant context for athletes regardless of the specific compound.